DPP4 and periodontitis: The hormone glucose-dependent insulinotropic polypeptide (GIP), which is elevated by dipeptidyl peptidase-4 (DPP-4) inhibitors (incretin-related drugs) for the treatment of type 2 diabetes, has been shown to suppress inflammation in experimental periodontitis [137].